메뉴 건너뛰기




Volumn 7, Issue , 2013, Pages 1471-1479

Disease-modifying drugs in Alzheimer's disease

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Diagnosis; Disease modifying drugs; Memantine; Treatment

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; AVAGACESTAT; BAPINEUZUMAB; BEGACESTAT; BETA SECRETASE INHIBITOR; CHF 5074; CHOLINESTERASE INHIBITOR; CRENEZUMAB; DAVUNETIDE; DIMEBON; DONEPEZIL; GALANTAMINE; GAMMA SECRETASE INHIBITOR; GANTENERUMAB; GLITAZONE DERIVATIVE; HUPERZINE A; LADOSTIGIL; MEMANTINE; METHYLENE BLUE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENSERINE; PIOGLITAZONE; PLACEBO; PONEZUMAB; RIVASTIGMINE; ROSIGLITAZONE; SEMAGACESTAT; SOLANEZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANUTIDE CRIDIFICAR;

EID: 84889578354     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S41431     Document Type: Review
Times cited : (81)

References (50)
  • 1
    • 0019972810 scopus 로고
    • The cholinergic hypothesis of geriatric memory dysfunction
    • Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408-414.
    • (1982) Science , vol.217 , pp. 408-414
    • Bartus, R.T.1    Dean III, R.L.2    Beer, B.3    Lippa, A.S.4
  • 2
    • 0022645755 scopus 로고
    • The cholinergic hypothesis ten years on
    • Perry EK. The cholinergic hypothesis ten years on. Br Med Bull. 1986;42:63-69.
    • (1986) Br Med Bull , vol.42 , pp. 63-69
    • Perry, E.K.1
  • 4
    • 0022457840 scopus 로고
    • Nicotinic acetylcholine binding sites in Alzheimer's disease
    • Whitehouse PJ, Martino AM, Antuono PG, et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 1986;371:146-151.
    • (1986) Brain Res , vol.371 , pp. 146-151
    • Whitehouse, P.J.1    Martino, A.M.2    Antuono, P.G.3
  • 5
    • 0030751425 scopus 로고    scopus 로고
    • Nicotinic acetylcholine involvement in Alzheimer's and Parkinson's disease: Implications for therapeutics
    • Newhouse PA, Potter A, Levin ED. Nicotinic acetylcholine involvement in Alzheimer's and Parkinson's disease: implications for therapeutics. Drugs Aging. 1997;11:206-228.
    • (1997) Drugs Aging , vol.11 , pp. 206-228
    • Newhouse, P.A.1    Potter, A.2    Levin, E.D.3
  • 6
    • 0035826771 scopus 로고    scopus 로고
    • Practice parameter: Management of dementia (an evidence-based review)
    • Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Neurology. 2001;56: 1154-1166.
    • (2001) Neurology , vol.56 , pp. 1154-1166
    • Doody, R.S.1    Stevens, J.C.2    Beck, C.3
  • 7
    • 0036063785 scopus 로고    scopus 로고
    • The tolerability and safety of cholinesterase inhibitors in the treatment of dementia
    • Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl. 2002;127:45-63.
    • (2002) Int J Clin Pract Suppl , vol.127 , pp. 45-63
    • Inglis, F.1
  • 8
    • 33645735618 scopus 로고    scopus 로고
    • Donepezil in Alzheimer's disease: An evidence-based review of its impact on clinical and economic outcomes
    • Knowles J. Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes. Core Evid. 2006;1:195-219.
    • (2006) Core Evid , vol.1 , pp. 195-219
    • Knowles, J.1
  • 9
    • 3042550038 scopus 로고    scopus 로고
    • Donepezil for Alzheimer's disease in clinical practice -the DONALD study
    • Froelich L, Gertz HJ, Heun R, et al. Donepezil for Alzheimer's disease in clinical practice -the DONALD study. Dement Geriatr Cogn Disord. 2004;18:37-43.
    • (2004) Dement Geriatr Cogn Disord , vol.18 , pp. 37-43
    • Froelich, L.1    Gertz, H.J.2    Heun, R.3
  • 10
    • 37649026816 scopus 로고    scopus 로고
    • Donepezil for dementia due to Alzheimer's disease
    • Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease Cochrane Database Syst Rev. 2003;3:CD001190.
    • (2003) Cochrane Database Syst Rev , vol.3
    • Birks, J.S.1    Harvey, R.2
  • 11
    • 3042567016 scopus 로고    scopus 로고
    • AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial
    • Courtney C, Farrell D, Gray R, et al. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004;363: 2105-2115.
    • (2004) Lancet , vol.363 , pp. 2105-2115
    • Courtney, C.1    Farrell, D.2    Gray, R.3
  • 13
    • 33644826545 scopus 로고    scopus 로고
    • Differential effects or rivastigmine, galantamine and donepezil on behavioral and psychological symptoms in patients with Alzheimer's disease: 18-month, randomized, open-label trial
    • Cumbo E. Differential effects or rivastigmine, galantamine and donepezil on behavioral and psychological symptoms in patients with Alzheimer's disease: 18-month, randomized, open-label trial. Prim Care Community Psychiatr. 2005;10:95-102.
    • (2005) Prim Care Community Psychiatr , vol.10 , pp. 95-102
    • Cumbo, E.1
  • 14
    • 84862615890 scopus 로고    scopus 로고
    • The cost-effectiveness of donepezil and rivastigmine in the treatment of Alzheimer's disease in Thailand private hospital
    • Pattanaprateep O, Phongchareonsuk P, Chaikledkaew U. The cost-effectiveness of donepezil and rivastigmine in the treatment of Alzheimer's disease in Thailand private hospital. Value Health. 2005;8:314-815.
    • (2005) Value Health , vol.8 , pp. 314-815
    • Pattanaprateep, O.1    Phongchareonsuk, P.2    Chaikledkaew, U.3
  • 15
    • 14744273100 scopus 로고    scopus 로고
    • Treatment of behavioural and psychiatric symptoms in dementia: Implications of recent safety warnings
    • Bullock R. Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Curr Med Res Opin. 2005;21:1-10.
    • (2005) Curr Med Res Opin , vol.21 , pp. 1-10
    • Bullock, R.1
  • 16
    • 84862619683 scopus 로고    scopus 로고
    • The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No 111): A systematic review and economic model
    • Bond M, Rogers G, Peters J, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No 111): a systematic review and economic model. Health Technol Assess. 2012;16:1-470.
    • (2012) Health Technol Assess , vol.16 , pp. 1-470
    • Bond, M.1    Rogers, G.2    Peters, J.3
  • 17
    • 33644974191 scopus 로고    scopus 로고
    • Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: A double-blind, head-to-head, randomized pilot study
    • Ancoli-Israel S, Amatniek J, Ascher S, Sadik K, Ramaswamy K. Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study. Alzheimer Dis Assoc Disord. 2005;19:240-245.
    • (2005) Alzheimer Dis Assoc Disord , vol.19 , pp. 240-245
    • Ancoli-Israel, S.1    Amatniek, J.2    Ascher, S.3    Sadik, K.4    Ramaswamy, K.5
  • 18
    • 84863669083 scopus 로고    scopus 로고
    • Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: A systematic review
    • Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open. 2012;2:e000917.
    • (2012) BMJ Open , vol.2
    • Farrimond, L.E.1    Roberts, E.2    McShane, R.3
  • 19
    • 84863989904 scopus 로고    scopus 로고
    • Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: A post-marketing surveillance study
    • Clerici F, Vanvacore N, Elia A, et al. Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study. Neurol Sci. 2012;33:23-31.
    • (2012) Neurol Sci , vol.33 , pp. 23-31
    • Clerici, F.1    Vanvacore, N.2    Elia, A.3
  • 20
    • 41049104686 scopus 로고    scopus 로고
    • Current pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians
    • Qaseem A, Snow V, Cross TJ Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148:370-378.
    • (2008) Ann Intern Med , vol.148 , pp. 370-378
    • Qaseem, A.1    Snow, V.2    Cross Jr., T.J.3
  • 21
    • 77956666900 scopus 로고    scopus 로고
    • Dimebon disappointment
    • Jones WR. Dimebon disappointment. Alzheimers Res Ther. 2010;2:25.
    • (2010) Alzheimers Res Ther , vol.2 , pp. 25
    • Jones, W.R.1
  • 22
    • 84862806815 scopus 로고    scopus 로고
    • Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors
    • Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Ther. 2012;134:8-25.
    • (2012) Pharmacol Ther , vol.134 , pp. 8-25
    • Tayeb, H.O.1    Yang, H.D.2    Price, B.H.3    Tarazi, F.I.4
  • 23
    • 79955444505 scopus 로고    scopus 로고
    • A phase II trial of huperzine A in mild to moderate Alzheimer disease
    • Rafii MS, Walsh S, Little JT, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011;76:1389-1394.
    • (2011) Neurology , vol.76 , pp. 1389-1394
    • Rafii, M.S.1    Walsh, S.2    Little, J.T.3
  • 24
    • 84858195896 scopus 로고    scopus 로고
    • New pharmacological strategies for treatment of Alzheimer's disease: Focus on disease-modifying drugs
    • Salomone S, Caraci F, Leggio GM, et al. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease-modifying drugs. Br J Clin Pharmacol. 2012;73:504-517.
    • (2012) Br J Clin Pharmacol , vol.73 , pp. 504-517
    • Salomone, S.1    Caraci, F.2    Leggio, G.M.3
  • 25
    • 84857709982 scopus 로고    scopus 로고
    • Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment
    • Weinreb O, Amit T, Bar-Am O, Youdim MB. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012;13:483-494.
    • (2012) Curr Drug Targets , vol.13 , pp. 483-494
    • Weinreb, O.1    Amit, T.2    Bar-Am, O.3    Youdim, M.B.4
  • 26
    • 0025899041 scopus 로고
    • Amyloid hypothesis deposition as the central event in the aetiology of Alzheimer's disease
    • Hardy J, Akksop D. Amyloid hypothesis deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991;12: 383-388.
    • (1991) Trends Pharmacol Sci , vol.12 , pp. 383-388
    • Hardy, J.1    Akksop, D.2
  • 28
    • 33847662852 scopus 로고    scopus 로고
    • Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide
    • Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101-112.
    • (2007) Nat Rev Mol Cell Biol , vol.8 , pp. 101-112
    • Haass, C.1    Selkoe, D.J.2
  • 29
    • 33644592598 scopus 로고    scopus 로고
    • Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study
    • Watson GS, Cholerton BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 2005;13:950-958.
    • (2005) Am J Geriatr Psychiatry , vol.13 , pp. 950-958
    • Watson, G.S.1    Cholerton, B.A.2    Reger, M.A.3
  • 30
    • 77956090575 scopus 로고    scopus 로고
    • Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: Results from a randomized, double-blind, placebo-controlled phase III study
    • Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30:131-146.
    • (2010) Dement Geriatr Cogn Disord , vol.30 , pp. 131-146
    • Gold, M.1    Alderton, C.2    Zvartau-Hind, M.3
  • 31
    • 84889601493 scopus 로고    scopus 로고
    • An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738) (EPOCH
    • Merck, Bethesda, MD: US National Library of Medicine, updated November 4, 2013], Accessed November 22, 2013
    • Merck. An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738) (EPOCH). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated November 4, 2013]. Available from: urlhttp://www.clinicaltrials.gov/ct2/show/NCT01739348?term=MK-8931&rank=2. NLM identifier: NCT01739348. Accessed November 22, 2013.
    • (2012) ClinicalTrials.gov [website On the Internet]
  • 32
    • 84889590080 scopus 로고    scopus 로고
    • Efficacy and Safety Trial of MK-8931 in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS)
    • Merck, Bethesda, MD: US National Library of Medicine, updated November 19, 2013]. Available from, Accessed November 22, 2013
    • Merck. Efficacy and Safety Trial of MK-8931 in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2013 [updated November 19, 2013]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01953601?term=MK-8931&rank=3. NLM identifier: NCT01953601. Accessed November 22, 2013.
    • (2013) ClinicalTrials.gov [website On the Internet]
  • 33
    • 33750151419 scopus 로고    scopus 로고
    • Assembly, trafficking and function of gamma-secretase
    • Kaether C, Haass C, Steiner H. Assembly, trafficking and function of gamma-secretase. Neurodegener Dis. 2006;3:275-283.
    • (2006) Neurodegener Dis , vol.3 , pp. 275-283
    • Kaether, C.1    Haass, C.2    Steiner, H.3
  • 34
    • 66349133387 scopus 로고    scopus 로고
    • Secretase inhibitors and modulators for Alzheimer's disease treatment
    • Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother. 2009;9:661-679.
    • (2009) Expert Rev Neurother , vol.9 , pp. 661-679
    • Tomita, T.1
  • 35
    • 66749084437 scopus 로고    scopus 로고
    • A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system
    • Bateman RJ, Siemers ER, Mawuenyega KG, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009;66:48-54.
    • (2009) Ann Neurol , vol.66 , pp. 48-54
    • Bateman, R.J.1    Siemers, E.R.2    Mawuenyega, K.G.3
  • 36
    • 79952529991 scopus 로고    scopus 로고
    • What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us
    • Schor NF. What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us. Ann Neurol. 2011;69:237-239.
    • (2011) Ann Neurol , vol.69 , pp. 237-239
    • Schor, N.F.1
  • 37
    • 84872320528 scopus 로고    scopus 로고
    • A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects
    • Dockens R, Wang JS, Castaneda L, et al. A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects. Clin Pharmacokinet. 2012;51:681-693.
    • (2012) Clin Pharmacokinet , vol.51 , pp. 681-693
    • Dockens, R.1    Wang, J.S.2    Castaneda, L.3
  • 38
    • 0033536163 scopus 로고    scopus 로고
    • Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
    • Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-177.
    • (1999) Nature , vol.400 , pp. 173-177
    • Schenk, D.1    Barbour, R.2    Dunn, W.3
  • 39
    • 20944448555 scopus 로고    scopus 로고
    • Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial
    • Gilman S, Koller M, Black RS. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553-1562.
    • (2005) Neurology , vol.64 , pp. 1553-1562
    • Gilman, S.1    Koller, M.2    Black, R.S.3
  • 40
    • 47149112621 scopus 로고    scopus 로고
    • Long-term effect of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial
    • Holmes C, Boche D, Wilkinson D, et al. Long-term effect of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216-223.
    • (2008) Lancet , vol.372 , pp. 216-223
    • Holmes, C.1    Boche, D.2    Wilkinson, D.3
  • 41
    • 84862331908 scopus 로고    scopus 로고
    • Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: Randomised, double-blind, placebo-controlled, first-in-human study
    • Winblad B, Andreasen N, Minthon L, et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012;11: 597-604.
    • (2012) Lancet Neurol , vol.11 , pp. 597-604
    • Winblad, B.1    Andreasen, N.2    Minthon, L.3
  • 42
    • 84884910087 scopus 로고    scopus 로고
    • Immunotherapy against amyloid pathology in Alzheimer's disease
    • Galimberti D, Ghezzi L, Scarpini E. Immunotherapy against amyloid pathology in Alzheimer's disease. J Neurol Sci. 2013;333:50-54.
    • (2013) J Neurol Sci , vol.333 , pp. 50-54
    • Galimberti, D.1    Ghezzi, L.2    Scarpini, E.3
  • 43
    • 84874138659 scopus 로고    scopus 로고
    • Bapineuzumab, an investigational agent for Alzheimer's disease
    • Khorassani F, Hilas O. Bapineuzumab, an investigational agent for Alzheimer's disease. P T. 2013;38:89-91.
    • (2013) P T , vol.38 , pp. 89-91
    • Khorassani, F.1    Hilas, O.2
  • 44
    • 84877254025 scopus 로고    scopus 로고
    • Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
    • Moreth J, Mavoungou C, Schindowski K. Passive anti-amyloid immunotherapy in Alzheimer's disease: what are the most promising targets? Immun Ageing. 2013;10:18.
    • (2013) Immun Ageing , vol.10 , pp. 18
    • Moreth, J.1    Mavoungou, C.2    Schindowski, K.3
  • 45
    • 79961230030 scopus 로고    scopus 로고
    • Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease
    • Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011;68:853-861.
    • (2011) Arch Gen Psychiatry , vol.68 , pp. 853-861
    • Tariot, P.N.1    Schneider, L.S.2    Cummings, J.3
  • 46
    • 79955546563 scopus 로고    scopus 로고
    • Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: Randomised controlled trial
    • Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry. 2011;198:351-356.
    • (2011) Br J Psychiatry , vol.198 , pp. 351-356
    • Forlenza, O.V.1    Diniz, B.S.2    Radanovic, M.3    Santos, F.S.4    Talib, L.L.5    Gattaz, W.F.6
  • 47
    • 34250615440 scopus 로고    scopus 로고
    • NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: Potential therapeutic role in brain disorders
    • Luna-Medina R, Cortes-Canteli M, Sanchez-Galiano S, et al. NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J Neurosci. 2007;27:5766-5776.
    • (2007) J Neurosci , vol.27 , pp. 5766-5776
    • Luna-Medina, R.1    Cortes-Canteli, M.2    Sanchez-Galiano, S.3
  • 49
    • 84878127734 scopus 로고    scopus 로고
    • A phase 2, double-blind, placebo-controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment
    • Morimoto BH, Schmechel D, Hirman J, et al. A phase 2, double-blind, placebo-controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. Dement Geriatr Cogn Disord. 2013;35:325-336.
    • (2013) Dement Geriatr Cogn Disord , vol.35 , pp. 325-336
    • Morimoto, B.H.1    Schmechel, D.2    Hirman, J.3
  • 50
    • 58149267462 scopus 로고    scopus 로고
    • Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau
    • Green KN, Steffan JS, Martinez-Coria H, et al. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci. 2008;28:11500-11510.
    • (2008) J Neurosci , vol.28 , pp. 11500-11510
    • Green, K.N.1    Steffan, J.S.2    Martinez-Coria, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.